UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
  
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the month of April 2022
 
 
Commission File Number:  001-39034
 
 
BELLUS HEALTH INC.

(Name of registrant)


275 Armand-Frappier Blvd.
Laval, Québec
H7V 4A7
Canada

(Address of principal executive offices)

 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
 
☐ Form 20-F
☒ Form 40-F
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



BELLUS Health Inc.
 




 




 




 
Date: April 25, 2022

By:
/s/ Ramzi Benamar
 


Name:
Ramzi Benamar
 


Title:
Chief Financial Officer
 

Form 6-K Exhibit Index
 
Exhibit
Number
 
Document Description
 
 
 
 

Exhibit 99.1

BELLUS Health Inc.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7


BELLUS Health to Participate in Multiple Upcoming Investor Conferences

LAVAL, Quebec – April 25, 2022 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that the Company’s management team will participate in multiple upcoming investor conferences.


Presentation Details:

Event: 2022 Bloom Burton & Co. Healthcare Investor Conference
Date/Time: Monday, May 2nd, 2022 at 10:30 a.m. ET
Format: In person corporate presentation
Location: Toronto, Canada

Event: I&I Event hosted by LifeSci Capital
Date/Time: Tuesday, May 10th, 2022 at 2:30 p.m. ET
Format: Virtual fireside chat

Event: RBC Capital Markets Global Healthcare Conference
Date/Time: Wednesday, May 18th, 2022 at 2:35 p.m. ET
Format: In person fireside chat
Location: New York, NY

Event: H.C. Wainwright Global Investment Conference
Date/Time: Wednesday, May 25th, 2022 at 12:30 p.m. ET
Format: In person corporate presentation
Location: Miami Beach, FL

Webcasts from the presentations may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health’s website at www.bellushealth.com. Following the events, archived webcasts will be available on the Company’s website.
 
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other cough hypersensitivity indications. The Company's product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC. BELLUS is planning a Phase 3 program, which is expected to begin in the second half of 2022.

Chronic cough is a cough lasting longer than eight weeks and when the cause of chronic cough cannot be identified or the cough persists despite treatment of all identified associated causes, the condition is referred to as RCC. It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options are limited.

BELLUS Health Inc.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7



The Company is exploring the potential use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

FOR MORE INFORMATION, PLEASE CONTACT:
Ramzi Benamar
Chief Financial Officer
rbenamar@bellushealth.com

Media:
Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com

Source: BELLUS Health Inc.